{"doc_id": "32779728", "type of study": "Therapy", "title": "", "abstract": "Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-Protocol and statistical analysis plan.\nSevere acute respiratory syndrome coronavirus-2 has caused a pandemic of coronavirus disease (COVID-19) with many patients developing hypoxic respiratory failure.\nCorticosteroids reduce the time on mechanical ventilation, length of stay in the intensive care unit and potentially also mortality in similar patient populations.\nHowever, corticosteroids have undesirable effects, including longer time to viral clearance.\nClinical equipoise on the use of corticosteroids for COVID-19 exists.\nThe COVID STEROID trial is an international, randomised, stratified, blinded clinical trial.\nWe will allocate 1000 adult patients with COVID-19 receiving \u226510\u00a0L/min of oxygen or on mechanical ventilation to intravenous hydrocortisone 200\u00a0mg daily vs placebo (0.9% saline) for 7\u00a0days.\nThe primary outcome is days alive without life support (ie mechanical ventilation, circulatory support, and renal replacement therapy) at day 28.\nSecondary outcomes are serious adverse reactions at day 14; days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90, and 1\u00a0year; and health-related quality of life at 1\u00a0year.\nWe will conduct the statistical analyses according to this protocol, including interim analyses for every 250 patients followed for 28\u00a0days.\nThe primary outcome will be compared using the Kryger Jensen and Lange test in the intention to treat population and reported as differences in means and medians with 95% confidence intervals.\nThe COVID STEROID trial will provide important evidence to guide the use of corticosteroids in COVID-19 and severe hypoxia.\n\u00a9 2020 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.\n", "Evidence Map": {"Enrollment": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 49}, {"term": "severe hypoxia ( COVID STEROID )", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 86}, {"term": "adult", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 27}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 50}, {"term": "\u226510", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 64}, {"term": "min of oxygen", "negation": "affirmed", "UMLS": {}, "start": 69, "end": 82}, {"term": "mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 111}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia ( COVID STEROID ) trial-Protocol and statistical analysis plan .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 49}, {"term": "severe hypoxia ( COVID STEROID )", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 86}], "Intervention": [{"term": "Low-dose hydrocortisone", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 23}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "Severe acute respiratory syndrome coronavirus-2 has caused a pandemic of coronavirus disease ( COVID-19 ) with many patients developing hypoxic respiratory failure .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "Corticosteroids reduce the time on mechanical ventilation , length of stay in the intensive care unit and potentially also mortality in similar patient populations .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Corticosteroids", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 15}], "Outcome": [{"term": "time on mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 57}, {"term": "length of stay in the intensive care unit", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 101}, {"term": "mortality", "negation": "affirmed", "UMLS": {}, "start": 123, "end": 132}], "Observation": [{"term": "reduce", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 22}], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "However , corticosteroids have undesirable effects , including longer time to viral clearance .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "corticosteroids", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 25}], "Outcome": [{"term": "effects", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 50}, {"term": "time to", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 77}], "Observation": [{"term": "undesirable", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 42}, {"term": "longer", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 69}], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "Clinical equipoise on the use of corticosteroids for COVID-19 exists .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The COVID STEROID trial is an international , randomised , stratified , blinded clinical trial .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We will allocate 1000 adult patients with COVID-19 receiving \u226510 L / min of oxygen or on mechanical ventilation to intravenous hydrocortisone 200 mg daily vs placebo ( 0.9 % saline ) for 7 days .", "Evidence Elements": {"Participant": [{"term": "adult", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 27}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 50}, {"term": "\u226510", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 64}, {"term": "min of oxygen", "negation": "affirmed", "UMLS": {}, "start": 69, "end": 82}, {"term": "mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 111}], "Intervention": [{"term": "intravenous hydrocortisone", "negation": "affirmed", "UMLS": {}, "start": 115, "end": 141}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 158, "end": 165}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome is days alive without life support ( ie mechanical ventilation , circulatory support , and renal replacement therapy ) at day 28 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "mechanical ventilation", "negation": "negated", "UMLS": {}, "start": 60, "end": 82}, {"term": "circulatory support", "negation": "negated", "UMLS": {}, "start": 85, "end": 104}, {"term": "renal replacement therapy", "negation": "negated", "UMLS": {}, "start": 111, "end": 136}], "Outcome": [{"term": "days alive without life support", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 54}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Secondary outcomes are serious adverse reactions at day 14 ; days alive without life support at day 90 ; days alive and out of hospital at day 90 ; all-cause mortality at day 28 , day 90 , and 1 year ; and health-related quality of life at 1 year .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "serious adverse reactions", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 48}, {"term": "days alive without life support", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 92}, {"term": "days alive and out of hospital at day 90", "negation": "negated", "UMLS": {}, "start": 105, "end": 145}, {"term": "all-cause mortality", "negation": "negated", "UMLS": {}, "start": 148, "end": 167}, {"term": "health-related", "negation": "negated", "UMLS": {}, "start": 206, "end": 220}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We will conduct the statistical analyses according to this protocol , including interim analyses for every 250 patients followed for 28 days .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome will be compared using the Kryger Jensen and Lange test in the intention to treat population and reported as differences in means and medians with 95 % confidence intervals .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "DISCUSSION", "Text": "The COVID STEROID trial will provide important evidence to guide the use of corticosteroids in COVID-19 and severe hypoxia .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "\u00a9 2020 The Acta Anaesthesiologica Scandinavica Foundation . Published by John Wiley & Sons Ltd .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}